Buyer beware: On the QR code-based drug traceability framework

📌 Summary:

• Health Ministry expanded Schedule H2 drugs from a curated brand list to entire therapeutic classes — a shift from revenue-based to risk-based regulation
• Schedule H2 (introduced 2022-23) mandates a barcode/QR code on each pack, now encoding a product identifier, manufacturing licence number and batch number to trace defective batches
• Causal chain: counterfeit networks target vaccines, cancer drugs and antimicrobials → substandard antimicrobials cause sub-therapeutic dosing → selection pressure worsens India''s already high antimicrobial resistance (AMR); the NCB flags medicinal opioids/psychotropics leaking into illicit markets
• Addresses recurring US FDA and European Medicines Agency quality-control concerns; the USTR repeatedly names India a leading source of counterfeit medicines (after contaminated cough-syrup episodes)
• The Jan Vishwas Act 2026 now distinguishes procedural from substantial non-compliance — only the latter draws meaningful enforcement
• Solutions/challenges: needs a state-managed real-time database accessible to pharmacists and regulators, plus interoperable scanning infrastructure across States; pharmacists and consumers must habitually verify packs; packaging + IT compliance will strain MSME manufacturers; sensitive prescription data on controlled substances needs a digital-governance layer that does not yet exist
• Whether it improves India''s reputation as a pharmacy ultimately hinges on implementation

🎯 UPSC Relevance: GS2 — regulation of the health/pharma sector, consumer safety and transparency; links to AMR (global health) and ease-of-doing-business reforms.

📝 Prelims Facts:

• Schedule H2 introduced 2022-23; mandates QR/barcode authentication on drug packs
• Jan Vishwas Act 2026 decriminalises procedural non-compliance
• WHO flags high volumes of fake antimicrobials in low- and middle-income countries
• Bodies referenced: US FDA, European Medicines Agency, USTR, Narcotics Control Bureau (NCB)

🔑 Key Term: Antimicrobial Resistance (AMR) — when microbes evolve to resist drugs; substandard/sub-therapeutic dosing accelerates it.